Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026)
Viatris' (VTRS) quarterly Liabilities and Shareholders Equity came in at $36.8 billion in Q1 2026, down 4.26% year-on-year from $38.5 billion in Q1 2025, and down 0.96% quarter-over-quarter from $37.2 billion in Q4 2025.
Viatris (VTRS) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Viatris' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $36.8 billion for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 4.26% year-over-year to $36.8 billion in Q1 2026; TTM through Mar 2026 was $150.4 billion, a 11.58% decrease from a year earlier, with the FY2025 full-year figure at $37.2 billion, down 10.38% from the prior year.
- Liabilities and Shareholders Equity declined to $36.8 billion in Q1 2026 per VTRS's latest filing, from $37.2 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $53.5 billion in Q1 2022 and bottomed at $36.8 billion in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $47.3 billion (2024), against an average of $45.0 billion.
- Across the five-year window, Liabilities and Shareholders Equity rose 0.16% in 2023 and declined 18.73% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $50.0 billion in 2022, then decreased by 4.67% to $47.7 billion in 2023, then decreased by 12.97% to $41.5 billion in 2024, then slipped by 10.38% to $37.2 billion in 2025, then slipped by 0.96% to $36.8 billion in 2026.
- Per Business Quant, the three latest VTRS Liabilities and Shareholders Equity figures stand at $36.8 billion (Q1 2026), $37.2 billion (Q4 2025), and $37.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 6.71 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 25.35 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 928.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.83 Bn |
| Dec 31, 2025 | 37.19 Bn |
| Sep 30, 2025 | 37.92 Bn |
| Jun 30, 2025 | 38.41 Bn |
| Mar 31, 2025 | 38.47 Bn |
| Dec 31, 2024 | 41.50 Bn |
| Sep 30, 2024 | 44.75 Bn |
| Jun 30, 2024 | 45.33 Bn |
| Mar 31, 2024 | 47.34 Bn |
| Dec 31, 2023 | 47.69 Bn |
| Sep 30, 2023 | 48.74 Bn |
| Jun 30, 2023 | 48.70 Bn |
| Mar 31, 2023 | 49.29 Bn |
| Dec 31, 2022 | 50.02 Bn |
| Sep 30, 2022 | 48.66 Bn |
| Jun 30, 2022 | 51.13 Bn |
| Mar 31, 2022 | 53.47 Bn |
| Dec 31, 2021 | 54.84 Bn |
| Sep 30, 2021 | 56.07 Bn |
| Jun 30, 2021 | 57.98 Bn |